Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias

Q4 Medicine
José Tuñón , Ana María Pello-Lázaro , Marta López-Castillo , Álvaro Aceñaa
{"title":"Anticuerpos monoclonales inhibidores de la proproteína convertasa subtilisina/kexina tipo 9: nuevas evidencias","authors":"José Tuñón ,&nbsp;Ana María Pello-Lázaro ,&nbsp;Marta López-Castillo ,&nbsp;Álvaro Aceñaa","doi":"10.1016/S1131-3587(20)30025-X","DOIUrl":null,"url":null,"abstract":"<div><p>Monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) increase recycling of low-density lipoprotein receptors, and reduce plasma levels of these lipoproteins by 50-60%. Moreover, these agents also decrease lipoprotein(a) levels and increase high-density lipoprotein levels, as well as having other beneficial effects on lipid metabolism. clínically, these drugs decrease the incidence of cardiovascular events in patients with chronic atherosclerosis and in those who have recently experienced acute coronary syndrome. Furthermore, in these patients, the use of alirocumab has been associated with lower overall mortality. Patients with extensive atherosclerosis, diabetic patients and those with a low-density lipoprotein level &gt;100 mg/dL achieve the greatest clínical benefits. In general, these drugs are safe and appear to offer an excellent additional tool for treating dyslipidemia. Today, the challenge is to promote the use of these agents in patients with cardiovascular disorders in order to improve their prognosis.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S113135872030025X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

Monoclonal antibodies that target proprotein convertase subtilisin/kexin type 9 (PCSK9) increase recycling of low-density lipoprotein receptors, and reduce plasma levels of these lipoproteins by 50-60%. Moreover, these agents also decrease lipoprotein(a) levels and increase high-density lipoprotein levels, as well as having other beneficial effects on lipid metabolism. clínically, these drugs decrease the incidence of cardiovascular events in patients with chronic atherosclerosis and in those who have recently experienced acute coronary syndrome. Furthermore, in these patients, the use of alirocumab has been associated with lower overall mortality. Patients with extensive atherosclerosis, diabetic patients and those with a low-density lipoprotein level >100 mg/dL achieve the greatest clínical benefits. In general, these drugs are safe and appear to offer an excellent additional tool for treating dyslipidemia. Today, the challenge is to promote the use of these agents in patients with cardiovascular disorders in order to improve their prognosis.

抑制枯草素/克辛9型原蛋白转换酶的单克隆抗体:新的证据
针对蛋白转化酶枯草素/克辛9型(PCSK9)的单克隆抗体增加了低密度脂蛋白受体的再循环,并将这些脂蛋白的血浆水平降低了50-60%。此外,这些药物还能降低脂蛋白(a)水平,增加高密度脂蛋白水平,并对脂质代谢有其他有益作用。Clínically,这些药物降低了慢性动脉粥样硬化患者和最近经历过急性冠状动脉综合征的患者心血管事件的发生率。此外,在这些患者中,使用alirocumab与较低的总死亡率相关。广泛动脉粥样硬化患者、糖尿病患者和低密度脂蛋白水平为100mg /dL的患者获益最大clínical。总的来说,这些药物是安全的,似乎为治疗血脂异常提供了一个很好的额外工具。今天的挑战是促进这些药物在心血管疾病患者中的使用,以改善他们的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信